|

Autologous tumor infiltrating lymphocytes (TILs) Clinical Trials

1 actively recruiting trial

Also known as: LM103

Pipeline

Phase 1: 1

Top Sponsors

  • Suzhou BlueHorse Therapeutics Co., Ltd.1

Indications

  • Melanoma1
  • Cervical Carcinoma1
  • Lung Cancer1
  • Non Small Cell Lung Cancer1
  • Cancer1

Other1 trial

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.